How large is the neuromuscular blocking drug market, and what is its growth trajectory?
The neuromuscular blocking drug market size has grown strongly in recent years. It will grow from $3.87 $ billion in 2024 to $4.08 $ billion in 2025 at a compound annual growth rate (CAGR) of 5.5%. The growth in the historic period can be attributed to increased prevalence of conditions, increased awareness and training, increased healthcare spending, improved drug reversibility, and rise emphasis on patient safety.
The neuromuscular blocking drug market size is expected to see strong growth in the next few years. It will grow to $4.98 $ billion in 2029 at a compound annual growth rate (CAGR) of 5.1%. The growth in the forecast period can be attributed to regulatory approvals, growth in outpatient and day surgeries, the expansion of medical tourism and strategic alliances, the growing prevalence of musculoskeletal disorders, and the increasing prevalence of surgical procedures. Major trends in the forecast period include the development of non-sedative formulations, the development of new NMBDs, advances in personalized medicine, the development of combination therapies, and patient-centric drug development.
Get Your Free Sample of The Global Neuromuscular Blocking Drug Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19612&type=smp
What are the key forces behind the neuromuscular blocking drug market’s growth in recent years?
The increasing number of surgical procedures is expected to propel the growth of the neuromuscular blocking drug market going forward. Surgical procedures are medical operations involving incisions, excisions, or other techniques to treat injuries, diseases, or conditions. The increasing number of surgical procedures is due to improved diagnostic tools, greater access to healthcare, a focus on the quality of life, and rising patient awareness and expectations. Neuromuscular blocking drugs are used in surgical procedures to induce muscle relaxation and facilitate various aspects of the operation. For instance, in September 2023, according to a report published by the American Society of Plastic Surgeons, a US-based professional society, in 2022, a total of 26.2 million surgical and minimally invasive cosmetic and reconstructive procedures were carried out in the United States. Therefore, the increasing prevalence of surgical procedures drives the growth of the neuromuscular blocking drug market.
What are the major segments of the neuromuscular blocking drug market?
The neuromuscular blocking drugmarket covered in this report is segmented –
1) By Type: Non-Polarizing Agents, Depolarizing Agents
2) By Application: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others Applications
3) By End-Users: Hospitals, Homecare, Specialty Clinics, Other End-Users
Subsegments:
1) By Non-Polarizing Agents: Benzylisoquinolines, Steroidal Agents, Long-Acting Agents, Intermediate-Acting Agents, Short-Acting Agents,
2) By Depolarizing Agents: Succinylcholine, Analogues of Succinylcholine, Rapid-Onset Agents, Short-Acting Agents, Intermediate-Acting Agents
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/neuromuscular-blocking-drug-global-market-report
Which companies dominate the neuromuscular blocking drug market?
Major companies operating in the neuromuscular blocking drug market are Pfizer Inc., Merck & Co Inc., AbbVie Inc., Bayer AG, Fresenius Kabi AG, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Limited, Baxter International Inc., Astellas Pharma Inc., Daiichi Sankyo Company Limited, UCB Pharma S.A., Eisai Co Ltd., Ipsen S.A., B. Braun Melsungen AG, Aurobindo Pharma Limited, Hikma Pharmaceuticals PLC, Mallinckrodt Pharmaceuticals plc, Mylan N.V., Nippon Shinyaku Co Ltd., Sagent Pharmaceuticals Inc., Osmosis Inc., Cadila Healthcare Limited
What major trends will shape the neuromuscular blocking drug market during the forecast period?
Major companies operating in the neuromuscular blocking drug market focus on broadening their product offerings through strategic collaborations to expand their market reach and drive innovation in drug formulations and delivery methods. Strategic collaborations involve partnerships between companies to share resources and expertise, enhancing product development and market reach. For instance, in May 2022, BDR Pharma, an India-based pharmaceutical company, partnered with Varenyam Healthcare, an India-based certified pharmaceutical manufacturing company, to launch Sugmadex, a pioneering anesthesia drug that offers safe, rapid, and complete reversal of shallow, moderate, and deep neuromuscular block (NMB), effectively removing the anesthesia effect on the body. Unlike existing agents, Sugmadex effectively addresses profound NMB and reduces post-operative respiratory complications. Available in 2 ml and 5 ml single-dose vials, Sugmadex promises enhanced efficiency and patient safety, improving recovery rates.
What are the key regional dynamics of the neuromuscular blocking drug market, and which region leads in market share?
North America was the largest region in the neuromuscular blocking drug market in 2024. The regions covered in the neuromuscular blocking drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Neuromuscular Blocking Drug Market Report 2025 Offer?
The neuromuscular blocking drug market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
A neuromuscular blocking drug is a medication that interrupts the transmission of nerve impulses to muscles, leading to temporary paralysis of skeletal muscles. These drugs work by either blocking the action of acetylcholine (a neurotransmitter) at the neuromuscular junction, where nerves communicate with muscles, or by mimicking acetylcholine and overstimulating the muscle receptor, causing it to become unresponsive. Neuromuscular blocking drugs are primarily used in medical settings, particularly during surgeries or other medical procedures, to facilitate intubation (inserting a breathing tube) and ensure muscle relaxation.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19612
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
